Up­dat­ed: FDA ap­proves weight loss drug We­govy to re­duce car­dio­vas­cu­lar events

The FDA on Fri­day ex­pand­ed the la­bel for No­vo Nordisk’s pop­u­lar weight loss in­jec­tion We­govy, ap­prov­ing it as a treat­ment to re­duce the risk of car­dio­vas­cu­lar death, heart at­tack and stroke in adults with heart dis­ease who are al­so ei­ther obese or over­weight.

We­govy, al­so known as semaglu­tide, shined in the Phase III SE­LECT tri­al, where it cut ma­jor car­dio­vas­cu­lar risks by 20% and demon­strat­ed that the risk of death from car­dio­vas­cu­lar caus­es was 15% low­er in pa­tients get­ting the drug. The study, which en­rolled 17,604 pa­tients, is one of the largest and longest stud­ies to date in­ves­ti­gat­ing the GLP-1 in adults. Ma­jor ad­verse car­dio­vas­cu­lar events in­clude car­dio­vas­cu­lar death, non-fa­tal my­ocar­dial in­farc­tion or non-fa­tal stroke.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER